Let's TalkLet's TalkA controlled substance on a subscription, advertised in the two categories platforms restrict hardest - where staying live is most of the competitive advantage.
TRT sits at the intersection of two things platforms restrict hardest - prescription medication and sexual health - and the second problem is that patients lapse. We will review your creative against the rules that actually get accounts restricted, and model revenue per patient against how long they genuinely stay on protocol.
Local conditions that change the plan, rather than the state name pasted into a template.
A TRT patient is not a transaction, they are a monthly relationship measured in years, and the acquisition maths follows from that. A clinic pricing its campaigns against a first-month value is systematically underbidding against competitors who understand the lifetime figure. The discipline is knowing your actual retention curve rather than the one in the pitch deck, because the difference between eight months and twenty-four months of average tenure is the difference between two viable strategies.
Texas has enough population spread across Houston, DFW, San Antonio, Austin and El Paso that a clinic with a remote-capable model can build real volume without opening a second location. That is a structural advantage over smaller states, and it changes the targeting from a radius around a building to a state-level campaign with a small number of physical touchpoints for labs and injections.
Men's health advertising is crowded with anti-ageing claims, and a prospective patient has usually waded through several before reaching you. That makes restraint a differentiator: symptoms, lab work, what the protocol actually involves and what it will not fix. Clinics that match the loudest competitor's claims win the click and lose the consultation, because the patient arrives braced for a sales pitch.
The board that governs your advertising depends on the licence you hold, not only on the state. These are the rules that bite in Texas.
Under 22 TAC §174.5 and Tex. Occ. Code §111.005, a prescription issued through telemedicine must be for a legitimate medical purpose and arise from a proper practitioner-patient relationship. Advertising that promises a prescription, or implies the outcome before anyone has been assessed, pre-empts a clinical decision the rules reserve for the clinician. The campaign can promise an evaluation and a fast one; it cannot promise the result.
Remote prescribing of controlled substances currently operates under federal telemedicine flexibilities that have been extended repeatedly rather than made permanent. A clinic whose entire acquisition model assumes remote-only prescribing is building on a rule that has a review date. That is not a reason to avoid telehealth - it is a reason to have an in-person pathway ready and to know which share of your revenue depends on the flexibility continuing.
22 TAC Chapter 164 governs physician advertising in Texas and reaches false, misleading or deceptive claims as well as the use of testimonials, on which Texas takes a notably broad position. Men's health marketing leans heavily on transformation narratives and patient stories, which is exactly where this bites. We build the proof out of mechanism and process rather than out of patient accounts.
The same programme as everywhere, run against this state's rules.
The closest work we can show is the clinic network below - 54,000+ leads, cost per lead down 57%, scaled across twelve states. It was not a TRT practice and we will not dress it up as one. What transfers is the paid acquisition machinery and the lead-quality discipline at scale. What does not transfer is anything about controlled-substance prescribing or the Texas Medical Board's position on testimonials, which is why those sit above rather than being folded into a general pitch.
Read the full case studyNo, and this is the most common defect we see in the category. 22 TAC §174.5 and Tex. Occ. Code §111.005 require a prescription to serve a legitimate medical purpose within a proper practitioner-patient relationship, so advertising the outcome in advance pre-empts a clinical judgement that is not the marketer's to make. What you can promise is speed and clarity - an evaluation this week, lab work explained, a straight answer either way - which converts well and does not commit your clinician to anything.
It depends entirely on what share of your patients you have never seen in person, and most clinics have not calculated it. Remote prescribing of controlled substances has been running on federal flexibilities that were extended rather than settled, so the sensible posture is to know the number, keep an in-person pathway available, and avoid building a campaign whose whole promise is that nobody ever needs to visit. Your counsel should be tracking the current position rather than your agency.
Whatever your real retention curve supports, which is usually more than clinics assume and occasionally far less. This is a subscription business, so the governing number is average tenure multiplied by monthly margin, not the first payment. We ask for the actual cohort retention before setting targets, because a clinic bidding against a one-month value in an auction where competitors are bidding against a two-year value simply loses every worthwhile placement.
We would design the campaign not to need them. 22 TAC Chapter 164 reaches misleading advertising and testimonials, and Texas takes an unusually broad view of what counts in healthcare advertising. Men's health is also a category where transformation claims attract scrutiny on the ad platforms independently of the board. Proof built on protocol, monitoring and what the clinic will not promise tends to convert better with a sceptical buyer anyway.
For a clinic with a remote-capable model, usually yes. Texas has five metros large enough that a state-level campaign reaches meaningful volume without a second location, and the cost per acquisition outside the most contested areas is frequently better. The constraint is operational rather than marketing: lab logistics, injection options and an in-person pathway need to exist before the campaign creates demand in a city you have no presence in.
The full service, and the neighbouring states we cover.
Which metro, which procedures, and what you are running now. We will tell you honestly whether we can help, and what the board rules mean for it.